Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986

Journal of Clinical Oncology

Volumn 30, Issue 2, 2012, Pages 191-199

  De Santis, Maria ^a   Bellmunt, Joaquim ^b   Mead, Graham ^d   Kerst, J Martijn ^f   Leahy, Michael ^e   Maroto, Pablo ^c   Gil, Thierry ^h   Marreaud, Sandrine ⁱ   Daugaard, Gedske ^j   Skoneczna, Iwona ^k   Collette, Sandra ⁱ   Lorent, Julie ⁱ   De Wit, Ronald ^g   Sylvester, Richard ⁱ  

^a KAISER FRANZ JOSEF HOSPITAL   (Austria)

^b INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^e ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^f NETHERLANDS CANCER INSTITUTE   (Netherlands)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h JULES BORDET INSTITUTE   (Belgium)

ⁱ EORTC DATA CENTER   (Belgium)

^j Rigshospitalet   (Denmark)

^k INSTITUTE OF ONCOLOGY   (Poland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; METHOTREXATE; VINBLASTINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLADDER CANCER; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; INFECTION; INOPERABLE CANCER; KIDNEY DYSFUNCTION; KIDNEY PELVIS CANCER; LEUKOPENIA; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SURVIVAL TIME; THROMBOCYTOPENIA; URETER CANCER; URETHRA CANCER; URINARY TRACT CANCER; VISCERAL METASTASIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; SURVIVAL RATE; UROLOGIC NEOPLASMS; VINBLASTINE;

EID: 84855583390     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.3571     Document Type: Article

References (39)

1. Dash A, Galsky MD, Vickers AJ, et al: Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 107:506-513, 2006 (Pubitemid 44107210)
2. Balducci L: Evidence-based management of cancer in the elderly. Cancer Control 7:368-376, 2000
3. Balducci L, Extermann M: Management of cancer in the older person: A practical approach. Oncologist 5:224-237, 2000 (Pubitemid 30429942)
4. Balducci L, Yates J: General guidelines for the management of older patients with cancer. Oncology (Williston Park) 14:221-227, 2000
5. De Santis M, Bachner M: New developments in first- and second-line chemotherapy for transitional cell, squamous cell and adenocarcinoma of the bladder. Curr Opin Urol 17:363-368, 2007 (Pubitemid 47344625)
6. de Wit R, European Organization for Research and Treatment: Overview of bladder cancer trials in the European Organization for Research and Treatment. Cancer 97:2120-2126, 2003
7. Bellmunt J, Albanell J, Gallego OS, et al: Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy. Cancer 70:1974-1979, 1992
8. Bellmunt J, Ribas A, Eres N, et al: Carboplatinbased versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 80:1966-1972, 1997 (Pubitemid 27479792)
9. de Wit R, Tesselaar M, Kok TC, et al: Randomised phase II trial of carboplatin and iproplatin in advanced urothelial cancer. Eur J Cancer 27:1383-1385, 1991
10. Mottet-Auselo N, Bons-Rosset F, Costa P, et al: Carboplatin and urothelial tumors. Oncology 50:28-36, 1993 (suppl 2)
11. Klocker J, Pont J, Schumer J, et al: Carboplatin, methotrexate and vinblastin (Carbo-MV) for advanced urothelial cancer: A phase II trial. Am J Clin Oncol 14:328-330, 1991
12. Small EJ, Fippin LJ, Ernest ML, et al: A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium. Cancer 78:1775-1780, 1996 (Pubitemid 26330906)
13. Lorusso V, Pollera CF, Antimi M, et al: A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum: Italian Co-operative Group on Bladder Cancer. Eur J Cancer 34:1208-1212, 1998 (Pubitemid 28342111)
14. Pollera CF, Ceribelli A, Crecco M, et al: Weekly gemcitabine in advanced bladder cancer: A preliminary report from a phase I study. Ann Oncol 5:182-184, 1994 (Pubitemid 24062575)
15. Stadler WM, Kuzel T, Roth B, et al: Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15:3394-3398, 1997 (Pubitemid 27485860)
16. Moore MJ, Tannock IF, Ernst DS, et al: Gemcitabine: A promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 15:3441-3445, 1997 (Pubitemid 27527715)
17. Albers P, Siener R, Härtlein M, et al: Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma: Prognostic factors for response and improvement of quality of life. Onkologie 25:47-52, 2002 (Pubitemid 34224993)
18. von der Maase H: Gemcitabine in transitional cell carcinoma of the urothelium. Expert Rev Anticancer Ther 3:11-19, 2003
19. De Santis M, Bellmunt J, Mead G, et al: Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: Phase II-Results of EORTC study 30986. J Clin Oncol 27:5634-5639, 2009
20. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
21. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
22. Bajorin DF, Dodd PM, Mazumdar M, et al: Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17:3173-3181, 1999 (Pubitemid 29470648)
23. von der Maase H, Hansen SW, Roberts JT, et al: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068-3077, 2000
24. Castagneto B, Zai S, Marenco D, et al: Singleagent gemcitabine in previously untreated elderly patients with advanced bladder carcinoma: Response to treatment and correlation with the comprehensive geriatric assessment. Oncology 67:27-32, 2004 (Pubitemid 39370347)
25. Calabrò F, Lorusso V, Rosati G, et al: Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma. Cancer 115:2652-2659, 2009
26. Mir O, Alexandre J, Ropert S, et al: Combination of gemcitabine and oxaliplatin in urothelial cancer patients with severe renal or cardiac comorbidities. Anticancer Drugs 16:1017-1021, 2005 (Pubitemid 41416093)
27. Theodore C, Bidault F, Bouvet-Forteau N, et al: A phase II monocentric study of oxaliplatin in combination with gemcitabine (GEMOX) in patients with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract. Ann Oncol 17:990-994, 2006 (Pubitemid 43778992)
28. Cancer Care Ontario (CCO): Cisplatin User File, 2010
29. Lichtman SM, Wildiers H, Launay-Vacher V, et al: International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 43:14-34, 2007 (Pubitemid 46070218)
30. Raj GV, Iasonos A, Herr H, et al: Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancer. J Clin Oncol 24:3095-3100, 2006 (Pubitemid 46638946)
31. Dreicer R, Manola J, Roth BJ, et al: Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer 100:1639-1645, 2004 (Pubitemid 38456340)
32. Dogliotti L, Cartenì G, Siena S, et al: Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: Results of a randomized phase 2 trial. Eur Urol 52:134-141, 2007 (Pubitemid 46803003)
33. Petrioli R, Frediani B, Manganelli A, et al: Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients: A randomized phase II study. Cancer 77:344-351, 1996
34. von der Maase H, Sengelov L, Roberts JT, et al: Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23:4602-4608, 2005 (Pubitemid 46224062)
35. Sternberg CN, de Mulder P, Schornagel JH, et al: Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 42:50-54, 2006 (Pubitemid 41814532)
36. De Santis M, Sylvester R, Bellmunt J: Reply to G. Sonpavde et al. J Clin Oncol 28:e443-e444, 2010
37. Wedding U, Ködding D, Pientka L, et al: Physicians' judgement and comprehensive geriatric assessment (CGA) select different patients as fit for chemotherapy. Crit Rev Oncol Hematol 64:1-9, 2007 (Pubitemid 47362733)
38. Roehrig B, Hoeffken K, Pientka L, et al: How many and which items of activities of daily living (ADL) and instrumental activities of daily living (IADL) are necessary for screening. Crit Rev Oncol Hematol 62:164-171, 2007 (Pubitemid 46575271)
39. Extermann M, Aapro M, Bernabei R, et al: Use of comprehensive geriatric assessment in older cancer patients: Recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 55:241-252, 2005 (Pubitemid 41219694)